These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 28430174)

  • 41. Expression of activation-induced cytidine deaminase is associated with a poor prognosis of diffuse large B cell lymphoma patients treated with CHOP-based chemotherapy.
    Kawamura K; Wada A; Wang JY; Li Q; Ishii A; Tsujimura H; Takagi T; Itami M; Tada Y; Tatsumi K; Shimada H; Hiroshima K; Tagawa M
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):27-36. PubMed ID: 26077666
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations.
    Cao XX; Li J; Cai H; Zhang W; Duan MH; Zhou DB
    Ann Hematol; 2017 Nov; 96(11):1867-1871. PubMed ID: 28803429
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diffuse large B-cell lymphoma with MYC gene rearrangements: Current perspective on treatment of diffuse large B-cell lymphoma with MYC gene rearrangements; case series and review of the literature.
    de Jonge AV; Roosma TJ; Houtenbos I; Vasmel WL; van de Hem K; de Boer JP; van Maanen T; Lindauer-van der Werf G; Beeker A; Timmers GJ; Schaar CG; Soesan M; Poddighe PJ; de Jong D; Chamuleau ME
    Eur J Cancer; 2016 Mar; 55():140-6. PubMed ID: 26820684
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The long non-coding RNA NONHSAG026900 predicts prognosis as a favorable biomarker in patients with diffuse large B-cell lymphoma.
    Zhao S; Fang S; Liu Y; Li X; Liao S; Chen J; Liu J; Zhao L; Li H; Zhou W; Shen W; Dong X; Xiang R; Wang L; Zhao Y
    Oncotarget; 2017 May; 8(21):34374-34386. PubMed ID: 28423735
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CD109, a negative regulator of TGF-β signaling, is a putative risk marker in diffuse large B-cell lymphoma.
    Yokoyama M; Ichinoe M; Okina S; Sakurai Y; Nakada N; Yanagisawa N; Jiang SX; Numata Y; Umezawa A; Miyazaki K; Higashihara M; Murakumo Y
    Int J Hematol; 2017 May; 105(5):614-622. PubMed ID: 28032275
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Transforming growth factor β type II receptor as a marker in diffuse large B cell lymphoma.
    Mao S; Yang W; Ai L; Li Z; Jin J
    Tumour Biol; 2015 Dec; 36(12):9903-8. PubMed ID: 26168957
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical and Pathologic Correlation of Increased MYC Gene Copy Number in Diffuse Large B-Cell Lymphoma.
    Haws BT; Cui W; Persons DL; Zhang D
    Clin Lymphoma Myeloma Leuk; 2016 Dec; 16(12):679-683. PubMed ID: 27633159
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma.
    Zheng M; Perry AM; Bierman P; Loberiza F; Nasr MR; Szwajcer D; Del Bigio MR; Smith LM; Zhang W; Greiner TC
    Neuropathology; 2017 Dec; 37(6):509-516. PubMed ID: 28856744
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A novel missense mutation of the XBP1 gene in diffuse large B-cell lymphoma.
    Tate G; Kishimoto K; Hirayama Y; Suzuki T; Mitsuya T
    Cancer Genet Cytogenet; 2009 Apr; 190(2):131-3. PubMed ID: 19380033
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Next generation sequencing and the management of diffuse large B-cell lymphoma: from whole exome analysis to targeted therapy.
    Jardin F
    Discov Med; 2014; 18(97):51-65. PubMed ID: 25091488
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lack of topoisomerase copy number changes in patients with de novo and relapsed diffuse large B-cell lymphoma.
    Pedersen MØ; Poulsen TS; Gang AO; Knudsen H; Lauritzen AF; Pedersen M; Nielsen SL; Brown P; Høgdall E; Nørgaard P
    Exp Hematol; 2015 Jul; 43(7):534-6. PubMed ID: 25931012
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
    Li S; Desai P; Lin P; Yin CC; Tang G; Wang XJ; Konoplev SN; Khoury JD; Bueso-Ramos CE; Medeiros LJ
    Histopathology; 2016 Jun; 68(7):1090-8. PubMed ID: 26426741
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Keeping good and bad company: stromal cells in lymphoma.
    Delabie J
    Leuk Lymphoma; 2012 Sep; 53(9):1654-5. PubMed ID: 22680767
    [No Abstract]   [Full Text] [Related]  

  • 54. Genomic Profiling: Building a Continuum From Knowledge to Care.
    Chen HX; Abrams JS
    JAMA Oncol; 2015 Jul; 1(4):474-5. PubMed ID: 26181257
    [No Abstract]   [Full Text] [Related]  

  • 55. Validation of LymphGen classification on a 400-gene clinical next-generation sequencing panel in diffuse large B-cell lymphoma: real-world experience from a cancer center.
    Zhu ML; Drill E; Joffe E; Salles G; Delgado AR; Zelenetz A; Palomba ML; Arcila M; Dogan A
    Haematologica; 2024 Jul; 109(7):2326-2330. PubMed ID: 38497151
    [No Abstract]   [Full Text] [Related]  

  • 56. Exploring the genetic landscape of HCV-related B-cell lymphomas using whole exome sequencing.
    Armand M; Degaud M; Tesson B; Laurent C; Vavasseur M; Parisot M; Hoareau-Coudert B; Canioni D; Michot JM; Charlotte F; Meignin V; Laurent C; Traverse-Gléhen A; Damotte D; Bachy E; Besson C; Hermine O; Davi F; Couronné L
    Leukemia; 2023 Jun; 37(6):1388-1391. PubMed ID: 36914771
    [No Abstract]   [Full Text] [Related]  

  • 57. Genomic and transcriptomic characterization reveals B-cell hyperactivation and immune evasion in hepatitis B virus-associated diffuse large B-cell lymphoma.
    Qin W; Wang N; Shi Q; Sun R; Zheng Z; Fu D; Dong L; Li C; Zhang Y; Xu P; Cheng S; Qian Y; Feng Y; Wang L; Zhao W
    Clin Transl Med; 2023 Jun; 13(6):e1293. PubMed ID: 37288581
    [No Abstract]   [Full Text] [Related]  

  • 58. Response.
    Anderson WF; Rosenberg PS; Prat A; Perou CM; Sherman ME
    J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25717172
    [No Abstract]   [Full Text] [Related]  

  • 59. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing.
    Mareschal S; Pham-Ledard A; Viailly PJ; Dubois S; Bertrand P; Maingonnat C; Fontanilles M; Bohers E; Ruminy P; Tournier I; Courville P; Lenormand B; Duval AB; Andrieu E; Verneuil L; Vergier B; Tilly H; Joly P; Frebourg T; Beylot-Barry M; Merlio JP; Jardin F
    J Invest Dermatol; 2017 Sep; 137(9):1984-1994. PubMed ID: 28479318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.